NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.
Publication
, Journal Article
Haddad, RI; Nasr, C; Bischoff, L; Busaidy, NL; Byrd, D; Callender, G; Dickson, P; Duh, Q-Y; Ehya, H; Goldner, W; Haymart, M; Hoh, C; Hunt, JP ...
Published in: J Natl Compr Canc Netw
December 2018
The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E-mutated anaplastic thyroid carcinoma.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
December 2018
Volume
16
Issue
12
Start / End Page
1429 / 1440
Location
United States
Related Subject Headings
- United States
- Treatment Outcome
- Thyroidectomy
- Thyroid Neoplasms
- Thyroid Gland
- Societies, Medical
- Proto-Oncogene Proteins B-raf
- Protein Kinase Inhibitors
- Prognosis
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Haddad, R. I., Nasr, C., Bischoff, L., Busaidy, N. L., Byrd, D., Callender, G., … Gurski, L. A. (2018). NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. J Natl Compr Canc Netw, 16(12), 1429–1440. https://doi.org/10.6004/jnccn.2018.0089
Haddad, Robert I., Christian Nasr, Lindsay Bischoff, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, et al. “NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.” J Natl Compr Canc Netw 16, no. 12 (December 2018): 1429–40. https://doi.org/10.6004/jnccn.2018.0089.
Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, et al. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. J Natl Compr Canc Netw. 2018 Dec;16(12):1429–40.
Haddad, Robert I., et al. “NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.” J Natl Compr Canc Netw, vol. 16, no. 12, Dec. 2018, pp. 1429–40. Pubmed, doi:10.6004/jnccn.2018.0089.
Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh Q-Y, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. J Natl Compr Canc Netw. 2018 Dec;16(12):1429–1440.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
December 2018
Volume
16
Issue
12
Start / End Page
1429 / 1440
Location
United States
Related Subject Headings
- United States
- Treatment Outcome
- Thyroidectomy
- Thyroid Neoplasms
- Thyroid Gland
- Societies, Medical
- Proto-Oncogene Proteins B-raf
- Protein Kinase Inhibitors
- Prognosis
- Oncology & Carcinogenesis